Consistently, there is evidence showing that metformin exerts anti-inflammatory effects in mouse colitis: Di Fusco et al. reported that metformin reduced colonic inflammation by activating the AMP-activated protein kinase (AMPK) signaling pathway (Di Fusco et al., 2018); Lee et al. showed that metformin ameliorated colitis by suppressing STAT3 signaling via activating the AMPK signaling pathway (Lee et al., 2015). This evidence concerns the gene PRKAA1 and colitis.